Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P36575
UPID:
ARRC_HUMAN
Alternative names:
Cone arrestin; Retinal cone arrestin-3; X-arrestin
Alternative UPACC:
P36575; B5B0B9; Q5JT23; Q5JT24; Q6IBF5; Q96EN2
Background:
Arrestin-C, also known as Cone arrestin or Retinal cone arrestin-3, plays a pivotal role in retina-specific signal transduction, potentially binding to photoactivated-phosphorylated red/green opsins. This protein, encoded by the gene with accession number P36575, is integral to the proper functioning of visual processes.
Therapeutic significance:
Arrestin-C is linked to Myopia 26, X-linked, female-limited, a condition characterized by early onset high myopia and unique tigroid fundus changes. Understanding the role of Arrestin-C could open doors to potential therapeutic strategies for this and related visual disorders.